Clinical Trial Update: Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a long-acting antipsychotic with placebo in schizophrenia; the study has completed and reported efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Long-acting antipsychotic (unspecified)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED